1 / 15

Entrepreneurship in Biotechnology

Entrepreneurship in Biotechnology. Columbia University Graduate School of Arts and Sciences BIOT 4180. Week 10. Product Development: Clinical Development. Development Process. Decrease in productivity. Academia and Private Sector. Risk mitigation. Process. Phase 1: safety

mauli
Télécharger la présentation

Entrepreneurship in Biotechnology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180

  2. Week 10 Product Development: Clinical Development Columbia University GSAS BIOT 4180

  3. Development Process Columbia University GSAS BIOT 4180

  4. Decrease in productivity Columbia University GSAS BIOT 4180

  5. Academia and Private Sector Columbia University GSAS BIOT 4180

  6. Risk mitigation Columbia University GSAS BIOT 4180

  7. Process • Phase 1: safety • IND: Investigational New Drug • Apply to FDA for human dosing • FDA has 30 days to object • IRB approval • Small number of subjects, one dose • Records adverse events, monitor physiologic process • Efficacy signals in oncology, infectious disease Columbia University GSAS BIOT 4180

  8. Phase 2 trial • IIA: dosing • IIB: efficacy • Target dose for pivotal • Target indication, study design • Can do one at a time or many phase 2 trials • Small biotech companies do a minimum • Large pharma do wide range of studies • Rarely file NDA/BLA based on phase 2 data Columbia University GSAS BIOT 4180

  9. Phase 3 • Typically 2 trials per indication, multicenter • N=hundreds to thousands • Why do trials fail? • Poor design • Difficult identification of treatment group or endpoint • Poor statistics: gaussian distribution, power • Placebo groups perform better than historical • Poor oversight • The drug does not work Columbia University GSAS BIOT 4180

  10. Phase 3 considerations • Physiologic or made-up endpoint • ADAS-COG and other cognition tests • Pain scores • How reproducible is the entity being measured? • Surrogate endpoints: accelerated approval process • Dealing with drop-outs • Intent to treat vs per protocol • Ease of enrollment Columbia University GSAS BIOT 4180

  11. Post phase 3 • Successful trial • Second trial (unless oncology, unmet need) • If works: NDA, then PDUFA date (6-9 months) • If approved, marketing and phase 4 studies • Unsuccessful trial • Data review/ data mining • Await concurrent study completion • Tough to kill a molecule Columbia University GSAS BIOT 4180

  12. Decrease in # approved drugs Columbia University GSAS BIOT 4180

  13. Increase in orphan designations Columbia University GSAS BIOT 4180

  14. Orphan Designation Columbia University GSAS BIOT 4180

  15. Definitions • Accelerated approval: surrogate endpoint • Fast track designation: FDA facilitated communication • Priority review: 6 vs 10 months • SPA Special Protocol Assessment • PDUFA • IND process • NDA Columbia University GSAS BIOT 4180

More Related